ATE339968T1 - Verwendung von mglur5 antagonists zur herstellung von medikamenten zur behandlung von empfindlichen x syndrome, autismus und geistiger zurückgebliebenheit - Google Patents

Verwendung von mglur5 antagonists zur herstellung von medikamenten zur behandlung von empfindlichen x syndrome, autismus und geistiger zurückgebliebenheit

Info

Publication number
ATE339968T1
ATE339968T1 AT02757930T AT02757930T ATE339968T1 AT E339968 T1 ATE339968 T1 AT E339968T1 AT 02757930 T AT02757930 T AT 02757930T AT 02757930 T AT02757930 T AT 02757930T AT E339968 T1 ATE339968 T1 AT E339968T1
Authority
AT
Austria
Prior art keywords
autism
syndrome
treatment
sensitive
mental retardation
Prior art date
Application number
AT02757930T
Other languages
English (en)
Inventor
Mark F Bear
Kimberly M Huber
Stephen T Warren
Original Assignee
Univ Brown Res Found
Univ Emory
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Brown Res Found, Univ Emory filed Critical Univ Brown Res Found
Application granted granted Critical
Publication of ATE339968T1 publication Critical patent/ATE339968T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
AT02757930T 2001-04-02 2002-04-02 Verwendung von mglur5 antagonists zur herstellung von medikamenten zur behandlung von empfindlichen x syndrome, autismus und geistiger zurückgebliebenheit ATE339968T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US28091501P 2001-04-02 2001-04-02

Publications (1)

Publication Number Publication Date
ATE339968T1 true ATE339968T1 (de) 2006-10-15

Family

ID=23075151

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02757930T ATE339968T1 (de) 2001-04-02 2002-04-02 Verwendung von mglur5 antagonists zur herstellung von medikamenten zur behandlung von empfindlichen x syndrome, autismus und geistiger zurückgebliebenheit

Country Status (9)

Country Link
US (1) US6890931B2 (de)
EP (1) EP1392363B1 (de)
JP (1) JP2005500260A (de)
AT (1) ATE339968T1 (de)
AU (1) AU2002307049A1 (de)
CA (1) CA2442478C (de)
DE (1) DE60214846T2 (de)
ES (1) ES2272754T3 (de)
WO (1) WO2002078745A2 (de)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6916821B2 (en) * 2001-04-02 2005-07-12 Brown University Methods of treating disorders with Group I mGluR antagonists
CA2532036A1 (en) * 2003-07-11 2005-02-03 Merck & Co., Inc. Methods for identifying cell surface receptor protein modulators
SE0303419D0 (sv) * 2003-12-17 2003-12-17 Astrazeneca Ab New use 11
WO2005104836A2 (en) * 2004-04-16 2005-11-10 Albert Einstein College Of Medicine Of Yeshiva University Drosophila models for diseases affecting learning and memory
WO2006115057A1 (ja) * 2005-04-19 2006-11-02 Otsuka Pharmaceutical Factory, Inc. 人工髄液
WO2007002285A2 (en) * 2005-06-21 2007-01-04 The Trustees Of The University Of Pennsylvania Methods for treating neurological and psychiatric conditions
WO2007029063A2 (en) * 2005-07-29 2007-03-15 Ecole Polytechnique Federale De Lausanne (Epfl) Treatment and/or prevention of pervasive developmental disorders
US7531541B2 (en) * 2005-09-20 2009-05-12 Vanderbilt University Partial mGluR5 antagonists for treatment of anxiety and CNS disorders
JP5015166B2 (ja) 2005-11-08 2012-08-29 エフ．ホフマン−ラ ロシュ アーゲー ｍＧｌｕ５受容体アンタゴニストとしてのチアゾロ［４，５−ｃ］ピリジン誘導体
PL2083811T3 (pl) 2006-11-22 2017-05-31 Clinical Research Associates, Llc Sposoby leczenia zespołu downa, zespołu łamliwego chromosomu x oraz autyzmu
ES2446269T3 (es) * 2006-12-19 2014-03-06 The Board Of Trustees Of The University Of Illinois 3-Benzofuranil-4-indolil-maleimidas como potentes inhibidores de GSK-3 para trastornos neurodegenerativos
US8340770B2 (en) * 2007-06-26 2012-12-25 Durand Dominique M Controlling seizure activity with electrical stimulation
WO2009047303A2 (en) * 2007-10-12 2009-04-16 Novartis Ag Metabotropic glutamate receptor modulators for the treatment of pervasive developmental disorder
US20090167322A1 (en) * 2007-12-28 2009-07-02 Erik Edmund Magnuson Systems and method for classifying a substance
AU2010213683B2 (en) 2009-02-12 2016-04-21 Indiana University Research & Technology Corporation Material and methods for treating developmental disorders including comorbid and idiopathic autism
WO2011053636A1 (en) * 2009-10-27 2011-05-05 Mount Sinai School Of Medicine Methods of treating psychiatric or neurological disorders with mglur antagonists
US20130058915A1 (en) * 2010-03-02 2013-03-07 Children's Medica Center Corporation Methods and compositions for treatment of angelman syndrome and autism spectrum disorders
US20110294879A1 (en) 2010-05-28 2011-12-01 Xenoport, Inc. Method of treatment of fragile x syndrome, down's syndrome, autism and related disorders
WO2012009646A1 (en) 2010-07-15 2012-01-19 Xenoport, Inc. Methods of treating fragile x syndrome, down's syndrome, autism and related disorders
CA2808660A1 (en) * 2010-08-19 2012-02-23 Blanchette Rockefeller Neurosciences Institute Treatment of cognitive disorders associated with abnormal dendritic spines using pkc activators
US20130225623A1 (en) * 2010-10-27 2013-08-29 Mount Sinai School Of Medicine Methods of Treating Psychiatric or Neurological Disorders with MGLUR Antagonists
KR20150070187A (ko) * 2012-10-23 2015-06-24 에프. 호프만-라 로슈 아게 자폐 장애의 치료를 위한 ｍｇｌｕ２／３ 길항제
US10449216B2 (en) * 2013-09-13 2019-10-22 Georgia State University Research Foundation, Inc. Modulating drug effects against metabotropic glutamate receptor with extracellular calcium
HRP20200638T1 (hr) 2015-06-03 2020-07-10 F. Hoffmann - La Roche Ag Derivati etinila
EP4366739A4 (de) * 2021-07-08 2025-09-03 The Royal Institution For The Advancement Of Learning / Mcgill Univ Phosphodiesterasehemmer zur abschwächung von fragilen x-syndromsymptomen

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6197820B1 (en) 1998-04-06 2001-03-06 Uab Research Foundation Use of phenylglycine derivatives to decrease neuronal death caused by brain tumors and brain lesions
EP1002535A1 (de) * 1998-10-28 2000-05-24 Hrissanthi Ikonomidou Neue Verwendung von Glutamat-Antagonisten zur Behandlung von Krebs
US7034055B1 (en) * 1999-06-30 2006-04-25 Prescient Neuropharma Inc. 2-aminoindane analogs
EP1210338A2 (de) 1999-08-05 2002-06-05 IGT Pharma Inc. 1,4-diazepin-derivate zur behandlung von krankheiten des zentralen nervensystems
CN1313465C (zh) * 1999-08-19 2007-05-02 Nps药物有限公司 杂多环化合物及其用于制备代谢性谷氨酸受体拮抗剂的应用
US6313159B1 (en) 1999-08-20 2001-11-06 Guilford Pharmaceuticals Inc. Metabotropic glutamate receptor ligand derivatives as naaladase inhibitors

Also Published As

Publication number Publication date
AU2002307049A1 (en) 2002-10-15
DE60214846T2 (de) 2007-05-16
JP2005500260A (ja) 2005-01-06
EP1392363A2 (de) 2004-03-03
DE60214846D1 (de) 2006-11-02
CA2442478C (en) 2010-02-02
WO2002078745A3 (en) 2002-11-28
ES2272754T3 (es) 2007-05-01
US6890931B2 (en) 2005-05-10
US20030100539A1 (en) 2003-05-29
WO2002078745A2 (en) 2002-10-10
EP1392363B1 (de) 2006-09-20
CA2442478A1 (en) 2002-10-10

Similar Documents

Publication Publication Date Title
DE60214846D1 (de) Verwendung von mGLuR5 antagonists zur Herstellung von Medikamenten zur Behandlung von empfindlichen X Syndrome, Autismus und geistiger Zurückgebliebenheit
BR0316350A (pt) Diaminotriazóis úteis como inibidores de proteìna cinases
ATE337780T1 (de) Indoly-lsulphonyl-verbindungen zur behandlung von störungen des zns
DE60235083D1 (de) Substituierte tetracyclin-verbindungen zur behandlung von malaria
TR200101499T1 (tr) Azepinoindol türevleri, hazırlanmaları ve kullanımları.
MY140488A (en) Substituted oxazolidinones and their use in the field of blood coagulation
ATE253063T1 (de) 5-ht1f-agonisten
MXPA05014082A (es) Acidos biariloximetilarenocarboxilicos.
DE60208221D1 (de) Heterozyklische verbindungen zur behandlung von harnwegserkrankungen
DE69807587D1 (de) Quinazolin-4-on AMPA Antagonisten
YU79103A (sh) Derivati dihidro-benzo/b/ /1,4/diazepin-2-ona kao antagonisti mglur2 i receptora
GB0111186D0 (en) Novel compounds
ATE218342T1 (de) Verwendung von rifaximin als medikament zur behandlung von durch cryptosporidiose verursachten diarrhoeen
MY120976A (en) 2-amino-6-(2-substituted-4-phenoxy)- substituted- pyridines
DK1463735T3 (da) Imidazo-2,1-B -1,3,4-thiadiazol-sulfonamider
DE50201565D1 (de) 2-thio-subsituierte imidazolderivative und ihre verwendung in der pharmazie
TR200000907T2 (tr) Nötrofil elastaz inhibitörleri olarak pirolopirolon türevleri.
ATE290857T1 (de) Bretyliumhaltige zusammensetzungen und kits und deren verwendung zur vorbeugung und behandlung cardiovaskulärer erkrankungen
DE60225155D1 (de) 3-substituierte 6,7-dihydroxytetrahydroisochinolin-derivate zur verwendung als antibkaterielle mittel
ATE443060T1 (de) Benzoägüchinolinderivate zur behandlung von glaucom und kurzsichtigkeit
ID25478A (id) Agonis 5-ht1f
ATE464048T1 (de) Behandlung von alzheimer-krankheit und verwandten zuständen
ATE349210T1 (de) Pharazeutische zusammensetzungen aus anticholinergica und p38 kinase hemmern zur behandlung von erkrankungen der atemwege
BRPI0410026A (pt) derivados de 3-amino-croman quinolina
MXPA04001205A (es) Compuesto para eliminar y/o mitigar la anhedonia.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties